Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.34 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.34 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.32 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20231745 | 1.00 | CA2 (0.39) | CA2CES2CYP3A4ABCB11ADRA2B | |
| SCHEMBL20323861 | 1.00 | CA2 (0.39) | CA2CES2CYP3A4ABCB11ADRA2B | |
| SCHEMBL2840008 | 1.00 | CA2 (0.39) | CA2CES2CYP3A4ABCB11ADRA2B | |
| SCHEMBL20234834 | 1.00 | CA2 (0.39) | CA2CES2CYP3A4ABCB11ADRA2B | |
| SCHEMBL1327135 | 1.00 | CA2 (0.39) | CA2CES2CYP3A4ABCB11ADRA2B | |
| SCHEMBL3238976 | 1.00 | CA2 (0.39) | CA2CES2CYP3A4ABCB11ADRA2B | |
| SCHEMBL1477867 | 0.98 | — | — | |
| Hydrochloric Acid SCHEMBL29086086 | 0.95 | CA2 (0.35) | CA2CES2CYP3A4ABCB11ADRA2B | |
| SCHEMBL20323910 | 0.94 | CES2 (0.39) | CA2CES2CYP3A4ABCB11ADRA2B | |
| SCHEMBL27365601 | 0.94 | CES2 (0.39) | CA2CES2CYP3A4ABCB11ADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230000994-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | YALE UNIVERSITY | 2023-01-05 | — | — | US | disclosed |
| EP-2500729-A1 | Characterization of biochips containing self-assembled monolayers | The University of Chicago (US) | 2012-09-19 | — | — | EP | disclosed |
| US-20080159954-A1 | METAL CHELATES HAVING A PERFLUORINATED PEG RADICAL, PROCESSES FOR THEIR PREPARATION, AND THEIR USE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2008-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080159954-A1 | METAL CHELATES HAVING A PERFLUORINATED PEG RADICAL, PROCESSES FOR THEIR PREPARATION, AND THEIR USE | TFRC, FCGRT, SLC39A14 | CA2 3593/4885CES2 1139/4885CYP3A4 1958/4885 |
| US-20230000994-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | CRBN, ARAF, VHL | CA2 4045/4885CES2 3556/4885CYP3A4 4716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.